Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.285 per share.
- Transaction Volume: 5,954.026 shares (aggregated).
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Ms. E. Walmsley (CEO, GSK Consumer Healthcare). This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Performance Share Plan. There are no reported material changes to the company's operations or financial position in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of an insider share transaction.
Investor Verification Points
- Verify the total shareholding of Ms. E. Walmsley following this dividend reinvestment.
- Confirm the market price of GSK Ordinary Shares on July 14, 2016, to validate the transaction price of £16.285.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial results.